Arjo AB AI Stock Analysis
Want to see SE:ARJO.B full AI Analyst Report?
Arjo AB (ARJO.B) AI Stock Analysis
Arjo AB
(Nasdaq OMX AB:ARJO.B)
The overall score of 63 reflects a company with positive momentum and a credible profit improvement plan, weighed down by weak underlying profitability and cash generation. The strongest factors are the bullish technical trend and the positive earnings call, which highlighted solid organic growth and a clear EBIT improvement commitment. The primary risks are the low net margin and poor operating cash flow coverage, which make the current P/E of 25.4 appear expensive. The balance sheet is stable, providing a floor for the rating.
Arjo AB (ARJO.B) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 856.49M
- Dividend Yield
- 2.59%
- Average Volume (3M)
- 412.38K
- Price to Earnings (P/E)
- 27.6
- Beta (1Y)
- 0.47
- Revenue Growth
- -0.50%
- EPS Growth
- -17.58%
- Country
- Sweden
- Employees
- 7,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
Arjo AB Business Overview & Revenue Model
Company Description
Arjo AB (publ) is a global leader in providing medical devices and innovative solutions tailored for patients experiencing limited mobility and age-related health conditions. Operating across North America, Western Europe, and other international mar...
How the Company Makes Money
Arjo makes money primarily by selling and servicing medical devices and care equipment to healthcare providers (such as hospitals, nursing homes, and other care institutions), typically through a combination of direct sales and distributor channels d...
Arjo AB Earnings Call Summary
The call was predominantly positive, supported by 6% organic growth, stronger gross profit and adjusted EBIT, improved reported margins, higher operating cash flow, and lower leverage. Management also highlighted strong momentum in patient handling, North America, and Europe, along with a SEK 350 million EBIT improvement plan. Offsetting issues included higher restructuring costs, weaker quarterly performance in international and distributor-led markets, less favorable working capital, negative investment cash flow, revaluation losses, and uncertainty around the flu season's effect on the fourth quarter.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Arjo reiterated a SEK 350 million commitment of profit improvements until H1 2029, described as a SEK 350 million profit improvement it believes it will be able to deliver by mid-2029, with the improvement being EBIT improvement; restructuring costs were “conservatively mentioned,” the company hopes it “will not need all of this,” and “the majority will happen largely over the coming 18 months.” Arjo will report progress every quarter, present new financial targets during Q1 2027, publish the year-end report at the end of January, and report Q1 in April 2027.
Arjo AB Financial Statement Overview
Summary
Arjo's financials show a stable balance sheet with declining leverage, but profitability is a major concern. Margins have contracted significantly from 2021 peaks, with TTM net margin at just 3.2%. Cash flow has recovered from a weak 2022, but operating cash flow coverage of net income remains low at 0.39, indicating weak cash generation quality.
Income Statement
48NeutralBalance Sheet
62PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.12B | 11.00B | 11.29B | 10.98B | 9.98B | 9.07B |
| Gross Profit | 4.35B | 4.32B | 4.91B | 4.74B | 4.21B | 4.21B |
| EBITDA | 1.87B | 1.81B | 2.03B | 1.97B | 1.70B | 2.03B |
| Net Income | 361.00M | 334.00M | 498.00M | 480.00M | 449.00M | 742.00M |
Balance Sheet | ||||||
| Total Assets | 15.95B | 14.98B | 16.28B | 16.00B | 16.17B | 14.61B |
| Cash, Cash Equivalents and Short-Term Investments | 858.00M | 836.00M | 892.00M | 923.00M | 949.00M | 757.00M |
| Total Debt | 5.35B | 5.35B | 5.42B | 5.49B | 6.31B | 5.45B |
| Total Liabilities | 7.92B | 7.52B | 7.94B | 8.42B | 8.54B | 7.73B |
| Stockholders Equity | 8.03B | 7.46B | 8.34B | 7.58B | 7.62B | 6.88B |
Cash Flow | ||||||
| Free Cash Flow | 970.00M | 757.00M | 838.00M | 1.38B | 15.00M | 974.00M |
| Operating Cash Flow | 1.58B | 1.44B | 1.52B | 2.06B | 915.00M | 1.73B |
| Investing Cash Flow | -677.00M | -705.00M | -635.00M | -638.00M | -902.00M | -695.00M |
| Financing Cash Flow | -809.00M | -730.00M | -907.00M | -1.43B | 136.00M | -1.28B |
Arjo AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ARJO.B, the sentiment is Positive. The current price of 36.70 is above the 20-day moving average (MA) of 34.50, above the 50-day MA of 30.43, and above the 200-day MA of 26.93, indicating a bullish trend. The MACD of 1.98 indicates Positive momentum. The RSI at 81.71 is Negative, neither overbought nor oversold. The STOCH value of 71.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ARJO.B.
Arjo AB Peers Comparison
Overall Rating
SE:ALIF.B74Outperform
SE:ASKER67Neutral
SE:XVIVO64Neutral
SE:ARJO.B63Neutral
SE:BACTI.B53Neutral
SE:SEDANA49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | SEK 22.11B | 34.47 | 11.32% | 0.83% | 1.62% | 63.45% | |
| 67Neutral | SEK 28.26B | 37.38 | ― | 0.53% | ― | ― | |
| 64Neutral | SEK 6.25B | 48.51 | 5.89% | ― | 17.83% | 330.94% | |
| 63Neutral | SEK 10.00B | 27.59 | 4.65% | 2.59% | -0.50% | -17.58% | |
| 53Neutral | SEK 523.91M | 83.06 | 1.93% | ― | -0.51% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | SEK 912.91M | -26.45 | -3.88% | ― | 0.42% | 15.03% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ARJO.B | Arjo AB Class B | 36.70 | 7.09 | 23.95% | |
| SE:ALIF.B | AddLife AB Class B | 181.30 | 5.13 | 2.91% | |
| SE:XVIVO | Xvivo Perfusion AB | 198.40 | 33.40 | 20.24% | |
| SE:BACTI.B | Bactiguard Holding AB | 14.95 | -3.80 | -20.27% | |
| SE:SEDANA | Sedana Medical AB | 9.19 | -0.42 | -4.37% | |
| SE:ASKER | Asker Healthcare Group AB | 73.65 | -13.13 | -15.13% |
Arjo AB Corporate Events
Arjo Delivers Solid Q3 Growth and Unveils Profitability-Boosting Strategy
Arjo reported solid third-quarter performance, with net sales rising to SEK 2,849 million and organic growth of 6.0%, supported by improved gross margin and higher adjusted EBITDA and operating profit. North America and Europe delivered more than 6%...
Arjo Reshapes Geographic Segments to Align Reporting With New Operating Model
Arjo, a global provider of medical equipment and mobility-focused care solutions, designs products that support patient transfers, hygiene, disinfection, diagnostics, leg ulcer treatment, pressure injury and deep vein thrombosis prevention, and medic...
Arjo Sets October 22 Date for Q3 2026 Report and Investor Call
Healthcare equipment specialist Arjo, which employs around 7,000 people globally and has more than 65 years of experience, provides a broad range of solutions that support safe, dignified care and better outcomes for patients with mobility issues. It...
Arjo Launches New Strategy With 350 MSEK EBIT Improvement Target
Arjo AB, a global provider of healthcare equipment and mobility-focused care solutions such as patient transfer systems, hygiene and disinfection products, diagnostic tools, leg ulcer treatments and medical beds, is leveraging its nearly 70-year heri...
Arjo Names Polestar Executive Lisa Ekelund as New CFO
Arjo has appointed Lisa Ekelund as its new Chief Financial Officer and member of the Group management team, succeeding long-serving CFO Christofer Carlsson, who will depart in early 2027. Ekelund, currently CFO of Polestar Nordics and a board member...
Arjo Sets Capital Markets Day to Outline Profitability and Strategy Plans
Arjo will host a Capital Markets Day for analysts, institutional investors, and media at Epicenter in central Stockholm on September 24, 2026, with the event also streamed live. Presentations will run from 09:00 to 11:30 CEST, be held in English, and...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026
